p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating
peptide p28 (p28) in treating patients with recurrent or progressive central nervous system
tumors. Drugs used in chemotherapy, such as azurin-derived cell-penetrating peptide p28, work
in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing.